KOL Identification

A leading diagnostics player asked DeciBio to characterize the evolving NIPT market to help inform strategic positioning regarding menu offerings and technological approach

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

A top-10 scientific service provider wanted to quantify the size of the CGT services market and understand trends within

The ventures arm of a top-20 U.S. health system sought support developing a go-to-market strategy for RWD-augmented biobank offerings

A real-world data (RWD) provider wanted to identify key use cases, unmet needs, and future opportunities in the RWD market, with a particular focus on clinical, genomic, and pathology RWD and biopharma users.

A multi-billion dollar life science company needed pre diligence on a potential acquisition target